{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"omics_type":["Unknown"],"volume":["20(5)"],"submitter":["Kalhotra P"],"pubmed_abstract":["Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the treatment for diabetic patients. Recently, natural compounds have been proven to inhibit DPP-4 with fewer side effects. In this work, initially, molecular docking simulations revealed that a natural compound, Galangin, possess a binding energy of -24 KJ/mol and interaction residues SER 630 and TYR 547, that are responsible for potent DPP-4 inhibition. In vitro studies showed that galangin not only inhibits DPP-4 in a concentration-dependent manner but also regulates glucose levels, enabling the prol"],"journal":["International journal of molecular sciences"],"pagination":["E1228"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC6429117"],"repository":["biostudies-literature"],"pubmed_title":["Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes."],"pmcid":["PMC6429117"],"pubmed_authors":["Gallardo-Velazquez T","Chittepu VCSR","Osorio-Revilla G","Kalhotra P"],"additional_accession":[]},"is_claimable":false,"name":"Discovery of Galangin as a Potential DPP-4 Inhibitor That Improves Insulin-Stimulated Skeletal Muscle Glucose Uptake: A Combinational Therapy for Diabetes.","description":"Dipeptidyl peptidase-4 (DPP-4) is a well-known therapeutic drug target proven to reduce blood glucose levels in diabetes mellitus, and clinically, DPP-4 inhibitors are used in combination with other anti-diabetic agents. However, side effects and skeletal muscle health are not considered in the treatment for diabetic patients. Recently, natural compounds have been proven to inhibit DPP-4 with fewer side effects. In this work, initially, molecular docking simulations revealed that a natural compound, Galangin, possess a binding energy of -24 KJ/mol and interaction residues SER 630 and TYR 547, that are responsible for potent DPP-4 inhibition. In vitro studies showed that galangin not only inhibits DPP-4 in a concentration-dependent manner but also regulates glucose levels, enabling the prol","dates":{"release":"2019-01-01T00:00:00Z","publication":"2019 Mar","modification":"2026-04-30T23:55:33.574Z","creation":"2025-05-29T22:08:06.681Z"},"accession":"S-EPMC6429117","cross_references":{"pubmed":["30862104"],"doi":["10.3390/ijms20051228"]}}